Drug Profile
Testosterone prodrug - Lipocine
Alternative Names: LPCN-1144Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Lipocine
- Class Anabolic steroids; Androstenols; Antifibrotics; Hepatoprotectants; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Androgen receptor agonists; Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Non-alcoholic steatohepatitis
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Preclinical Hepatic fibrosis
Most Recent Events
- 11 Apr 2024 Efficacy and adverse events data from a phase II trial in Non-alcoholic steatohepatitis released by Lipocine
- 21 Jun 2023 Efficacy and adverse events data from a phase II LiFT trial for Non-alcoholic steatohepatitis presented at European Association for the Study of the Liver Congress (EASL-2023)
- 12 Dec 2022 Testosterone prodrug is still in phase-II trials for Non-alcoholic steatohepatitis in USA (Lipocine pipeline; December 2022)